CLINICAL TRIAL: STUDY OF THE RELATIVE SAFETY AND EFFICACY OF COLLAGENASE THERAPY

临床试验：胶原酶疗法的相对安全性和功效研究

• 批准号: 7950781
• 负责人: LAWRENCE C HURST
• 金额: $ 8.93万
• 依托单位: STATE UNIVERSITY NEW YORK STONY BROOK
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7950781
• 关键词: Affect; Clinical Research; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Contracture; Disease; Fingers; Funding; Grant; Injection of therapeutic agent; Institution; Pharmaceutical Preparations; Phase; Relative (related person); Research; Research Personnel; Resources; Rupture; Safety; Source; Testing; Tissues; United States National Institutes of Health; collagenase

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the study is to test whether an experimental drug called collagenase will dissolve and rupture the tissue causing the contracture of your finger(s)due to your Dupuytren's disease. If your finger has failed to respond to injection after three random injections, or if you still have other fingers affected by Dupuytren's disease after three random injections, you are eligible to participate in an extended phase of the study.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项研究的目的是测试一种名为胶原酶的实验性药物是否会溶解和破裂导致您的手指挛缩的组织。如果您的手指在三次随机注射后对注射没有反应，或者如果您的其他手指在三次随机注射后仍然受到Dupuytren病的影响，您有资格参加本研究的延长期。